100
Participants
Start Date
September 20, 2021
Primary Completion Date
October 31, 2025
Study Completion Date
August 31, 2026
Tafasitamab
Observational Study on safety and effectiveness of tafasitamab in combination with lenalidomide inPatients With Relapsed or Refractory DLBCL.
RECRUITING
Westchester Medical Center, Hawthorne
COMPLETED
Lankenau Medical Center, Wynnewood
RECRUITING
Thomas Jefferson University, Philadelphia
RECRUITING
American Oncology Partners of Maryland PA, Bethesda
RECRUITING
VA Medical Center - Durham, Durham
RECRUITING
Leo Jenkins Cancer Center/ECU School of Medicine, Greenville
RECRUITING
Levine Cancer Institute, Charlotte
RECRUITING
Alabama Oncology, Birmingham
RECRUITING
Clearview Cancer Institute, Huntsville
RECRUITING
Ohio Health Marion Area Physicians, Marion
RECRUITING
Tri County Hematology & Oncology Associates, Inc, Massillon
RECRUITING
Mercy Medical Center, Canton
RECRUITING
University of Michigan Comprehensive Cancer Center Michigan Medicine, Ann Arbor
RECRUITING
Henry Ford Health System, Detroit
RECRUITING
McFarland Clinic P.C., Ames
RECRUITING
Mission Cancer and Blood, Des Moines
RECRUITING
Froedtert & Medical College Clinics, Milwaukee
COMPLETED
Tulane Cancer Center, New Orleans
RECRUITING
Integris Cancer Institute of Oklahoma, Oklahoma City
RECRUITING
University of Texas MD Anderson Cancer Center, Houston
RECRUITING
University of California, Irvine Medical Center, Orange
RECRUITING
UW Medicine, Seattle
RECRUITING
Yakima Valley Memorial Hospital/North Star Lodge, Yakima
RECRUITING
Morristown Medical Center, Morristown
RECRUITING
Rutgers Cancer Institute of New Jersey, New Brunswick
Lead Sponsor
Incyte Corporation
INDUSTRY